Hypothesis

In aged hepatocytes, the primary lesion that abolishes Hedgehog (Shh) signaling during regeneration is not a failure of ligand production or SMO gene expression, but an age‑related depletion of cholesterol within the primary cilium membrane that prevents SMO accumulation, activation, and downstream GLI2 nuclear translocation.

Mechanistic Basis

1. Ciliary cholesterol as a SMO co‑factor – In young cells, SMO transitions from an inactive to an active conformation only after binding cholesterol (or oxysterols) within the ciliary lipid bilayer. This conformational change promotes SMO’s movement from periciliary compartments into the axoneme, where it can inhibit SUFU and allow GLI2 activator formation.
2. Age‑related ciliary lipid remodeling – Recent lipidomics studies show a decline in membrane cholesterol and enrichment of phospholipids with shorter acyl chains in aging tissues. Such alterations increase membrane fluidity and disrupt ordered lipid rafts that are essential for SMO’s ciliary retention.
3. Consequence for GLI processing – Without ciliary cholesterol, SMO remains trapped in periciliary vesicles, fails to relieve PTCH inhibition, and SUFU continues to promote GLI2 processing into a repressor form. This reproduces the phenotype of SMO loss‑of‑function observed in aged hepatocytes, even if Shh/Ihh ligands were experimentally supplied.
4. Link to downstream phenotypes – Reduced ciliary SMO activity diminishes transcription of Cyclin D1, FOXM1, and Ki67, impairing hepatocyte proliferation. Concurrently, loss of Shh‑mediated anti‑inflammatory signaling permits NF‑κB activation, explaining the paradoxical rise in inflammatory cytokines despite low basal ligand levels.

Experimental Design

Model – Use 20‑month‑old C57BL/6 mice subjected to partial hepatectomy (PH) or carbon tetrachloride (CCl4) injury; include young (3‑month) controls.

Interventions

• Cholesterol rescue: Administer cholesterol‑loaded methyl‑β‑cyclodextrin (MβCD‑chol) intravenously 2 h before injury to preferentially enrich ciliary membranes.
• Genetic rescue: Deliver AAV8‑StARD4 (cholesterol‑transfer protein) under a hepatocyte‑specific transporter (Alb) promoter to boost ciliary cholesterol synthesis.
• Controls: MβCD alone (cholesterol‑depleted), AAV8‑GFP, and vehicle.

Readouts (48‑72 h post‑injury)

• Immunofluorescence for acetylated α‑tubulin (cilium) and SMO; quantify ciliary SMO intensity per cilium.
• Western blot of nuclear vs cytoplasmic GLI2; assess GLI2 activator/repressor ratio.
• qPCR and immunohistochemistry for Cyclin D1, FOXM1, Ki67.
• Liver‑to‑body‑weight ratio, BrdU incorporation, and serum ALT/AST for functional regeneration.
• Lipidomics of isolated cilia to confirm cholesterol restoration.

Expected Outcomes

If the hypothesis is correct, cholesterol‑repleted aged mice will show:

• Restoration of SMO ciliary localization to levels comparable to young controls.
• Increased GLI2 activator fraction and decreased GLI2 repressor.
• Rescue of proliferative gene expression and hepatocyte proliferation rates to ~80 % of young.
• Improved liver mass recovery and reduced serum injury markers.
• No effect in young mice (to rule off‑target toxicity).

Potential Pitfalls & Alternatives

• Off‑target membrane effects: MβCD can extract cholesterol globally; using low‑dose, cilia‑targeted cholesterol (e.g., conjugated to Arl13b‑binding peptide) will mitigate this.
• Compensatory pathways: If cholesterol rescue fails to restore signaling, the defect may lie in IFT‑B subunits (e.g., IFT88) or in ciliary length/structure; subsequent experiments would measure IFT protein levels and axoneme morphology.
• Species differences: Validate findings in human aged liver organoids or precision‑cut liver slices treated with cholesterol‑MβCD.

By directly testing whether ciliary cholesterol loss is the nodal point that uncouples ligand availability from SMO activation, this hypothesis provides a clear, falsifiable mechanistic bridge between the observed multi‑level Shh signaling failure in aged hepatocytes and a tractable therapeutic target.